Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 17, 2007

Nano-Terra and 3M Enter Nanotech Partnership

  • Nano-Terra inked a multiyear development and licensing agreement with 3M . The agreement is designed to bring to market innovative, nanotechnology-based products and solutions made possible by nanoscale, molecular fabrication methods pioneered by Nano-Terra co-founder George Whitesides, Ph.D., at Harvard University and the company’s scientists.

    The Cambridge-based firm is employing the design and manipulation of molecular structures for the creation of new properties and functionalities in materials.

    "3M is an innovative, diversified technology company with a stable of well-known brands and is a global leader in commercializing nanotechnology,” notes Carmichael Roberts, vice chairman and co-founder of Nano-Terra. “As a first step, we are focusing on how our expertise in soft lithography and in molecular self-assembly can support 3M's own development work in certain application areas."

    The co-development work will be performed primarily at Nano-Terra's lab facilities in Cambridge, with frequent input from and milestone reviews by 3M.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »